MktsMarkets

Gyre Therapeutics, Inc.
NASDAQ: GYREKey statistics
GYRE News
Stories mentioning GYRE from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 22,519 | 37,195 | 30,564 | 26,771 | 22,058 | 27,872 | 25,488 | 25,225 |
| Cost of Goods Sold | 1,227 | 1,743 | 1,628 | 1,151 | 894.00 | 1,177 | 958.00 | 770.00 |
| Gross Profit | 21,292 | 35,452 | 28,936 | 25,620 | 21,164 | 26,695 | 24,530 | 24,455 |
| Operating Expenses | ||||||||
| Research & Development | 6,738 | 4,815 | 2,363 | 3,425 | 3,095 | 3,712 | 2,775 | 3,355 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 31,874 | 39,856 | 22,011 | 23,449 | 19,785 | 29,914 | 20,297 | 21,261 |
| Operating Income (Loss) | (9,355) | 118.00 | 6,925 | 2,171 | 2,273 | 665.00 | 4,233 | 3,194 |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 29.00 | (2,194) | 727.00 | (145.00) | 107.00 | (1,634) | (75.00) | (72.00) |
| Pretax Income | (9,237) | (66.00) | 7,629 | 2,238 | 4,635 | 772.00 | 3,930 | 6,035 |
| Tax Provision | 621.00 | 1,300 | 1,693 | 662.00 | 901.00 | 203.00 | 1,074 | 1,497 |
| Net Income (Loss) | (9,858) | (1,366) | 5,936 | 1,576 | 3,734 | 569.00 | 2,856 | 4,538 |
| Earnings Per Share (Basic) | (0.10) | (0.02) | 0.04 | 0.00 | 0.03 | 0.01 | 0.01 | 0.04 |
| Earnings Per Share (Diluted) | (0.10) | (0.01) | 0.03 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Weighted Average Shares Outstanding (Basic) | 91,317 | 89,345 | 90,850 | 89,119 | 86,421 | 85,095 | 85,644 | 85,502 |
| Weighted Average Shares Outstanding (Diluted) | 91,345 | 103,180 | 103,972 | 102,702 | 101,971 | 102,294 | 102,640 | 102,206 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About GYRE
Gyre Therapeutics, Inc. (NASDAQ: GYRE) is a stock listed on the Nasdaq Stock Market under the ticker symbol GYRE. It last traded at $4.26 (Nov 11, 2026, 4:00 PM ET), up 0.7% on the day. That gives Gyre Therapeutics a market capitalisation of $497.0M.
Over the past 52 weeks GYRE has traded between $3.97 and $9.14.
Revenue for the quarter ended Mar 31, 2026 was $22.5M; a net loss of $9.9M. Revenue was up 2.1% from $22.1M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $22.5M | -$9.9M | -43.8% |
| Dec 31, 2025 | $37.2M | -$1.4M | -3.7% |
| Sep 30, 2025 | $30.6M | $5.9M | 19.4% |
| Jun 30, 2025 | $26.8M | $1.6M | 5.9% |
From Gyre Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…